Products

EFAI NeuroSuite CT ICH Assessment System
EFAI
Neurology AI
The EFAI NeuroSuite CT ICH Assessment System is an AI-powered radiological computer-assisted triage and notification software that uses deep learning to automatically analyze non-contrast head CTs for acute intracranial hemorrhage, alerting workstations for prioritized review.

See all 1 product →

About EFAI

Ever Fortune.AI (EFAI) is a healthcare AI company that develops advanced technology to improve medical workflows and patient outcomes across various specialties. Their solutions are designed to assist physicians in interpreting medical images and providing objective information, aiming to reduce diagnostic time and costs, and allow more time for patient communication. EFAI’s product catalog includes AI-enabled medical software for image viewing and analysis, workflow management, remote access, reporting, and clinical notification workflows. They offer systems for chest X-ray interpretation, acute aortic syndrome detection, radiotherapy organ segmentation, bone scintigraphy computer-assisted detection, intracerebral hemorrhage detection, myocardial perfusion reporting, bone age assessment, STEMI detection, ECG analysis, and PACS. Many of their products have received regulatory clearances from both Taiwan’s TFDA and the U.S. FDA.

EFAI’s technology leverages natural language processing (NLP), convolutional neural networks (CNN), and recurrent neural networks (RNN). The company’s mission is to drive continuous innovation in big data and artificial intelligence within intelligent and precision medicine. They are actively expanding their presence in international markets, including ASEAN countries, Europe, and the United States, through strategic partnerships and distribution agreements. EFAI also focuses on developing AI adaptive radiotherapy platforms, which utilize real-time data analysis to dynamically adjust treatment plans, enhancing precision and minimizing side effects in cancer treatment.

Focus Areas

AI-driven diagnostic solutions cloud biomedical platforms medical big data radiology cardiology oncology neurology precision medicine digital medicine workflow optimization

Business Intelligence

TechnologyAI-enabled medical software for image viewing and analysis, workflow management, remote access, reporting, and clinical notification workflows. Utilizes deep learning algorithms, natural language processing (NLP), convolutional neural networks (CNN), and recurrent neural networks (RNN).

What Physicians Need to Know

AI-Driven Diagnostic Solutions
EFAI specializes in AI-powered software for various medical imaging analyses, including acute intracranial hemorrhage detection (NeuroSuite CT ICH Assessment System), pleural effusion assessment (ChestSuite XR Pleural Effusion Assessment System), acute aortic syndrome detection (CardioSuite CTA Acute Aortic Syndrome Assessment System), and appendicitis assessment (ERSUITE CT Appendicitis Assessment System).
Cloud Biomedical Platforms & Medical Big Data
The company offers cloud biomedical platforms and leverages medical big data to develop its AI applications. They originated from China Medical University (CMU) and have access to a large medical database from CMU hospital.
Radiology
EFAI provides AI solutions for radiology, including triage and notification software for various conditions. Their products assist in interpreting CT and X-ray images for conditions like intracranial hemorrhage, pleural effusion, and acute aortic syndrome.
Cardiology
EFAI has developed AI-powered software for cardiology, such as the CardioSuite CTA Acute Aortic Syndrome Assessment System, which analyzes CT angiography scans to detect signs of acute aortic syndrome. AI in cardiology can improve diagnosis, optimize treatment plans, and enhance ECG interpretation.
Oncology
In oncology, EFAI offers AI-assisted solutions for cancer radiotherapy, including organ contouring (RTSuite CT HN-Segmentation System and RTSuite CT HCAP-Segmentation System) and adaptive treatment evaluation. They are developing an AI Adaptive Radiotherapy Platform.
Neurology
EFAI's neurology solutions include the NeuroSuite CT ICH Assessment System for detecting acute intracranial hemorrhage and the NeuroSuite CT Midline Shift Assessment System for identifying midline shift on non-contrast head CTs.
Precision Medicine & Digital Medicine
EFAI is committed to innovative developments in smart medicine and precision medicine as a pioneer of digital healthcare. They aim to provide personalized and precision cancer treatment through AI.
Workflow Optimization
Many of EFAI's AI solutions are designed to enhance medical workflow and boost patient outcomes by prioritizing urgent cases, streamlining treatment planning, and accelerating image review. They also offer an Intelligent Health Check Scheduling System to optimize schedules and reduce patient waiting times.
Physician Tip

EFAI's AI solutions act as a 'clinical co-pilot' to assist physicians, rather than replacing their diagnosis. These tools are designed to prioritize high-risk cases, accelerate image review, and streamline administrative tasks, allowing physicians to focus on complex clinical decisions and patient interpretation. The systems provide real-time recognition and notifications for critical findings, aiming to reduce diagnostic variation and improve patient outcomes through faster diagnosis and intervention.

EFAI's AI software is designed for seamless integration into existing clinical environments. Their radiotherapy solutions, AutoSeg and AdaptInsight, connect directly to popular treatment planning systems like Eclipse, RayStation, Monaco, and Pinnacle via DICOM. Their diagnostic systems often integrate with PACS/RIS workstations for worklist prioritization and notifications. The bone age interpretation software can be customized to integrate with existing PACS systems in hospitals.

Products by EFAI

1 product in the directory

EFAI NeuroSuite CT ICH Assessment System
EFAI
Neurology AI
The EFAI NeuroSuite CT ICH Assessment System is an AI-powered radiological computer-assisted triage and notification software that uses deep learning to automatically analyze non-contrast head CTs for acute intracranial hemorrhage, alerting workstations for prioritized review.

What the Web Says

EverFortune.AI (EFAI) is a company specializing in AI-driven medical solutions, particularly in the healthcare IT sector. They have developed various clinical-grade medical AI products, including systems for lung CAD, pediatric growth assessment, intelligent health check scheduling, and adaptive radiotherapy. The company has shown significant growth, with a reported 312% year-on-year revenue increase in the first 11 months of 2024. EFAI has also secured numerous medical device certifications from Taiwan's TFDA and the U.S. FDA for a wide range of applications.

Overall: Mixed

Strengths

  • Clinical-grade medical AI products with multiple certifications (FDA, TFDA).
  • Offers solutions for various medical fields, including radiology, pediatrics, and oncology.
  • Demonstrated robust operational growth and revenue increase.
  • Products aim to reduce patient waiting times and improve efficiency in healthcare.
  • Focus on personalized and precision cancer treatment through AI adaptive radiotherapy.
  • Systems can integrate with existing PACS systems in hospitals.

Limitations

  • No specific product or employer reviews were found on G2, Glassdoor, Capterra, or Reddit directly for "EFAI" or "Everfortune.ai".
  • Some features of their products are still under review or available as "Research Features".
  • One Reddit thread mentions a company called "EVERAI" with fraudulent charges, but it is unclear if this is related to Everfortune.ai.
  • General AI patient engagement software can be difficult for some users to grasp.
  • No public pricing or API information for some related AI visibility products.

Based on reviews from: G2, Glassdoor, Capterra, Healthcare IT reviewers, Reddit

Last updated: 2026-10-23

Videos

News, demos, and interviews about EFAI.

Loading videos...

Videos load interactively. If none appear, search YouTube for EFAI →

View all on YouTube

Press & Coverage

Healthcare+ B2B
Ever Fortune.AI medical software nets one more approval for the US market
Ever Fortune.AI announced on September 26, 2025, that its “EFAI RT Suite CT HCAP-Segmentation System” has received FDA approval, marking its 7th US approval and 11th from Taiwan's FDA. This AI-driven software automatically delineates 17 types of head-and-neck organs-at-risk on CT images for radiotherapy planning.
2025-09
Healthcare+ B2B
Ever Fortune. AI Expands Dual US-Taiwan Footprint with Appendicitis AI Approval, Accumulating 57 Global Permits
On August 18, 2026, Ever Fortune.AI announced that its EFAI ERSUITE CT APPENDICITIS ASSESSMENT SYSTEM received Taiwan FDA clearance, following its US FDA 510(k) clearance in April 2026. This brings the company's total global medical device certifications to 57, including 15 from the US FDA.
2026-08
Healthcare+ B2B
Ever Fortune.AI Partners with Hospitals to Build an AI-Driven Radiotherapy Platform, Targeting AI Healthcare Opportunities
On December 6, 2024, Ever Fortune.AI announced partnerships with Varian, China Medical University, Kaohsiung Veterans General Hospital, and Tungs' Taichung MetroHarbor Hospital to develop an AI Adaptive Radiotherapy Platform. The company has secured 41 medical device certifications globally, and reported a 312% year-on-year revenue increase in the first 11 months of the year.
2024-12
Healthcare+ B2B
Everfortune AI Expects Revenue Growth Acceleration in H2 2026, Targets Doubled Shipments for ABO Robot in 2027
Everfortune AI Co., Ltd. expects increased operational momentum in the second half of 2026, with revenue drivers including the release of deferred hospital procurement demand and volume production of the ABO robot. The company aims to double ABO unit shipments to 200 in 2027 and is developing a next-generation ABO model.
2026-08
Healthcare+ B2B
Ever Fortune AI Technology's AI-Powered Endotracheal Tube Depth Detection System Secures FDA Clearance
On February 21, 2025, Ever Fortune AI Technology Co., Ltd. announced that its Endotracheal Tube Depth Detection System received U.S. FDA clearance. The system uses deep learning algorithms to analyze chest X-ray images for potential vertical malposition of endotracheal tubes, enhancing patient safety.
2025-02
BigGo Finance
Ever Fortune.AI (6841.TW) Announces Capital Increase Record Date for Employee Stock Option Conversion
On February 1, 2026, Ever Fortune.AI announced a capital increase from the exercise of employee stock options, issuing 25,000 new common shares at NT$22 per share, raising NT$250,000 (approximately USD 7,900).
2026-02
Healthcare+ B2B
Ever Fortune. AI Obtains TFDA Approval for AI Appendicitis Detection System, Bringing Global Regulatory Clearances to 57
On August 24, 2026, Ever Fortune. AI's self-developed "Ever Fortune. AI Appendicitis Detection System" received medical device approval from the Taiwan Food and Drug Administration (TFDA). This follows its U.S. FDA 510(k) clearance in April 2026, bringing the company's total global regulatory approvals to 57.
2026-08
Institute for Biotechnology and Medicine Industry (IBMI)
Ever Fortune.AI (EFAI) to Increase Stake in EverBot Technology; FDA Milestone Achieved
This article from IBMI mentions Ever Fortune.AI's plans to increase its stake in EverBot Technology and highlights an FDA milestone achieved by EFAI.
unknown

Frequently Asked Questions

EFAI provides AI algorithms designed to assist in the analysis of medical images (radiology), ECGs and other cardiac data (cardiology), tumor identification and characterization (oncology), and neurological disorder detection from various scans (neurology). These solutions aim to enhance diagnostic accuracy and efficiency across these key specialties.
EFAI's cloud biomedical platform is designed for interoperability, utilizing standard APIs to integrate with existing EHR and PACS systems. It offers robust capabilities for secure storage, management, and advanced analytics of large-scale medical data, enabling insights for precision medicine and research.
EFAI's core products include AI-powered diagnostic aids, predictive analytics tools for patient management, and digital health platforms that streamline administrative tasks and clinical workflows. These solutions aim to reduce physician burnout, improve patient throughput, and support remote patient monitoring in digital medicine initiatives.
EFAI prioritizes data privacy and adheres to stringent regulatory standards such as HIPAA, GDPR, and relevant FDA guidelines. Our platforms incorporate robust security measures, encryption, and anonymization protocols to ensure patient data confidentiality and regulatory compliance at every level.
EFAI offers flexible pricing models tailored to the scale and needs of healthcare organizations, including subscription-based and per-use options. We provide comprehensive technical support, including 24/7 assistance and dedicated account management. We actively seek partnerships with healthcare providers and research institutions to co-develop and implement innovative AI solutions.
EFAI is a well-funded and rapidly growing company with a strong commitment to long-term innovation in healthcare AI. Our roadmap includes continuous development of more sophisticated AI algorithms, expansion into new medical specialties, and further integration of our platforms to support a holistic approach to precision and digital medicine.

Related Companies

A2z Radiology AI is a Boston-based medical imaging AI company that develops software for comprehensive CT interpretation, initially focusing on abdomen-pelvis CT scans. The company’s primary goal is to enhance diagnostic accuracy and efficiency in medical imaging for healthcare providers by leveraging artificial intelligence. Their flagship product, a2z-Unified-Triage, is FDA-cleared radiological computer-aided triage and notification […]

Perimeter Medical Imaging AI is a medical technology company dedicated to transforming cancer surgery through the use of ultra-high-resolution, real-time, advanced imaging tools. The company’s mission is to address significant unmet medical needs in cancer surgery, particularly concerning positive margins and the resulting need for re-excisions. Their proprietary technology, including the S-Series Optical Coherence Tomography […]

SOPHiA GENETICS is a healthcare AI company that has developed a cloud-native, AI-driven SaaS platform called SOPHiA DDM™. This platform is designed to enable hospitals, clinical laboratories, academic medical centers, and biopharmaceutical companies to analyze and interpret complex genomic, radiomic, and multimodal healthcare data. The company’s mission is to democratize data-driven medicine, providing actionable insights […]

Koios Care is a neurology-focused digital medicine company based in Antwerp, Belgium, specializing in AI-powered platforms. The company aims to revolutionize the management of neurological and chronic conditions, with an initial focus on Parkinson’s Disease. Koios Care’s platform utilizes everyday devices like smartphones and smartwatches to passively collect and analyze data, transforming it into objective, […]

Qure.ai is a leading healthcare AI company that leverages deep learning and artificial intelligence to revolutionize medical imaging diagnostics and make healthcare more accessible and affordable globally. The company develops AI-powered solutions for interpreting X-rays and CT scans, addressing critical health needs in areas such as lung, musculoskeletal, cardiovascular, and neurocritical health. Their technology assists […]

Deep Bio is a healthcare AI company that develops deep learning-based cancer diagnostic support software, aiming to advance patient outcomes by empowering clinicians with innovative technology. Their mission is to provide tools that enable medical professionals to make critical decisions, ultimately enhancing healthcare delivery and allowing clinicians to focus more on patient care. The company’s […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.